Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373938 | 0.90 | SMN1; SMN2 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL2373945 | 0.89 | NAMPT (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL24139180 | 0.89 | SMN1; SMN2 (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL31681838 | 0.89 | ROCK1 (0.54) | CYP3A4CYP2C9MAPTCYP2D6ROCK2 | |
| SCHEMBL2373426 | 0.89 | ROCK1 (0.54) | CYP3A4CYP2C9MAPTCYP2D6ROCK2 | |
| SCHEMBL29072859 | 0.86 | MMP13 (0.48) | SMN1; SMN2HTTROCK2ROCK1ALDH1A1 | |
| SCHEMBL669856 | 0.86 | MMP13 (0.48) | SMN1; SMN2HTTROCK2ROCK1ALDH1A1 | |
| SCHEMBL2374577 | 0.86 | MPL (0.46) | SMN1; SMN2ROCK2ROCK1HPGDSMAPK1 | |
| SCHEMBL12254348 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C9CYP2C19POLB | |
| SCHEMBL2373434 | 0.84 | TRPV4 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410397-B2 | Methods of enhancing cell survival of stem cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4585589-A2 | STEM CELL CULTURES | The Scripps Research Institute (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-4296270-B1 | A COMPOSITION COMPRISING STEM CELL CULTURES | SCRIPPS RESEARCH INST (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4296270-A2 | A COMPOSITION COMPRISING STEM CELL CULTURES | The Scripps Research Institute (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3936508-B1 | A COMPOSITION COMPRISING STEM CELL CULTURES | SCRIPPS RESEARCH INST (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4206319-A1 | INDUCTION OF PLURIPOTENT CELLS | The Scripps Research Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3235901-B1 | INDUCTION OF PLURIPOTENT CELLS | SCRIPPS RESEARCH INST (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3936508-A1 | A COMPOSITION COMPRISING STEM CELL CULTURES | The Scripps Research Institute (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3936508-A1 | A COMPOSITION COMPRISING STEM CELL CULTURES | The Scripps Research Institute (US) | 2022-01-12 | — | — | EP | disclosed |
| US-20210403862-A1 | METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2021-12-30 | — | — | US | disclosed |
| US-20110294761-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294761-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294761-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-01 | — | — | US | disclosed |
| US-8044201-B2 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044201-B2 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044201-B2 | Stem cell cultures | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110224233-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224233-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224233-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010065721-A1 | STEM CELL CULTURES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294761-A1 | STEM CELL CULTURES | NES, CD44, MCL1 | CYP1A2 4791/4885CYP3A4 4850/4885CYP2C9 4875/4885 |
| US-12410397-B2 | Methods of enhancing cell survival of stem cells | MCL1, BCL2, BCLAF1 | CYP1A2 4865/4885CYP3A4 4875/4885CYP2C9 4885/4885 |
| US-20210403862-A1 | METHODS OF ENHANCING CELL SURVIVAL OF STEM CELLS | MCL1, BCL2, BCLAF1 | CYP1A2 4865/4885CYP3A4 4875/4885CYP2C9 4885/4885 |
| US-20110224233-A1 | STEM CELL CULTURES | NES, CD44, MCL1 | CYP1A2 4791/4885CYP3A4 4850/4885CYP2C9 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.